Vaughn McCall, M.D., M.S., professor and chairman of the Department of Psychiatry and Behavioral Medicine, told a special consensus panel at the National Institutes of Health (NIH) that he could find no evidence that randomized controlled clinical trials had ever been conducted for five of the 10 pharmaceuticals prescribed most often for chronic insomnia.

None of the 10 are currently approved for insomnia, though all are FDA-approved as antidepressants, antipsychotics or sedatives, he said.

The NIH State-of-the-Science Conference on Manifestations and Management of Chronic Insomnia in Adults, sponsored by the National Institute of Mental Health and Office of Medical Applications Research, will continue through Wednesday, seeking to build consensus on a series of questions on chronic insomnia.

"There is widespread use of off-label prescribed medications for insomnia," said McCall, who directs the sleep laboratory at Wake Forest Baptist. But he said that evidence to support their effectiveness is poor.

He said that during the 1990s, the use of FDA-approved sleep medications called hypnotics declined by 54 percent between 1987 and 1996, "while the use of trazodone (Desyrel) and other sedating antidepressants rose by 146 percent. This trend continued through 2002, such that trazodone became the most frequently used medication for the treatment of insomnia."

He said that 78 percent of psychiatrists now make trazodone their first choice.

"In addition to trazodone, a wide variety of antidepressants, antipsychotics and sedatives gained favor for the treatment of insomnia despite the fact that none of these medications are approved for the treatment of insomnia."

McCall said the widespr
'"/>

Contact: Robert Conn
rconn@wfubmc.edu
336-716-4587
Wake Forest University Baptist Medical Center
14-Jun-2005